Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN lessened its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 17.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 96,952 shares of the specialty pharmaceutical company’s stock after selling 20,063 shares during the period. Wells Fargo & Company MN owned approximately 0.16% of Jazz Pharmaceuticals worth $11,940,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of JAZZ. Centre Asset Management LLC purchased a new position in Jazz Pharmaceuticals in the fourth quarter valued at $9,335,000. Moloney Securities Asset Management LLC acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $464,000. Franklin Resources Inc. boosted its stake in shares of Jazz Pharmaceuticals by 4.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after buying an additional 48,708 shares during the period. Hennion & Walsh Asset Management Inc. grew its position in shares of Jazz Pharmaceuticals by 13.7% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company’s stock worth $4,420,000 after buying an additional 4,332 shares in the last quarter. Finally, Sanctuary Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 502.8% during the third quarter. Sanctuary Advisors LLC now owns 11,754 shares of the specialty pharmaceutical company’s stock worth $1,310,000 after buying an additional 9,804 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now directly owns 439,744 shares in the company, valued at approximately $53,785,088.64. This trade represents a 0.34 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 1,140 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $137.81, for a total value of $157,103.40. Following the sale, the chief accounting officer now owns 7,012 shares of the company’s stock, valued at $966,323.72. This trade represents a 13.98 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,736 shares of company stock worth $4,023,305. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Up 1.1 %

Shares of NASDAQ:JAZZ opened at $102.91 on Wednesday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $6.25 billion, a P/E ratio of 14.49, a P/E/G ratio of 1.04 and a beta of 0.42. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06. The firm has a fifty day moving average price of $128.93 and a 200 day moving average price of $122.56.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Truist Financial boosted their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Barclays reissued an “overweight” rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. HC Wainwright lifted their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a report on Monday, March 10th. JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Finally, Cantor Fitzgerald cut Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.